These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19035337)

  • 1. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels.
    Yilmaz Y; Ulukaya E; Dolar E
    Hepatology; 2009 Feb; 49(2):697; author reply 697. PubMed ID: 19035337
    [No Abstract]   [Full Text] [Related]  

  • 2. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments.
    Yilmaz Y; Kurt R; Kalayci C
    Biomark Med; 2010 Oct; 4(5):743-5. PubMed ID: 20945987
    [No Abstract]   [Full Text] [Related]  

  • 3. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers.
    Mitry RR; De Bruyne R; Quaglia A; Hughes RD; Dhawan A
    Hepatology; 2007 Dec; 46(6):2047-8; author reply 2048. PubMed ID: 18046726
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis.
    Li X; Zhang Y; Wu K; Fan D
    Hepatology; 2010 May; 51(5):1865-6. PubMed ID: 20041411
    [No Abstract]   [Full Text] [Related]  

  • 5. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD.
    Fitzpatrick E; Mitry RR; Quaglia A; Hussain MJ; DeBruyne R; Dhawan A
    J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):500-6. PubMed ID: 20808246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of asymptomatic elevated serum aminotransferase levels, particularly in nonalcoholic steatohepatitis].
    Oldenburg B; Van Berge Henegouwen GP
    Ned Tijdschr Geneeskd; 1999 Mar; 143(10):506-9. PubMed ID: 10321258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis.
    Talwalkar JA
    Hepatology; 2009 Oct; 50(4):1000-3. PubMed ID: 19787817
    [No Abstract]   [Full Text] [Related]  

  • 9. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis.
    Bantel H; Bahr MJ; Schulze-Osthoff K
    Hepatology; 2009 Sep; 50(3):991. PubMed ID: 19593820
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver.
    Kim CH; Park JY; Lee KU; Kim JH; Kim HK
    Diabetes Metab Res Rev; 2009 Jan; 25(1):64-9. PubMed ID: 19065605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Ozturk O; Alahdab YO; Senates E; Colak Y; Doganay HL; Coskunpinar E; Oltulu YM; Eren F; Atug O; Tuncer I; Imeryuz N
    Dig Liver Dis; 2013 Jan; 45(1):58-62. PubMed ID: 22995553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.
    Sonsuz A; Basaranoglu M; Ozbay G
    Am J Gastroenterol; 2000 May; 95(5):1370-1. PubMed ID: 10811364
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and OGTT.
    Uygur-Bayramiçli O; Sargin M
    J Clin Gastroenterol; 2008 Feb; 42(2):219. PubMed ID: 18209601
    [No Abstract]   [Full Text] [Related]  

  • 14. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity.
    Emanuele E
    Hepatology; 2008 Dec; 48(6):2086-7; author reply 2087. PubMed ID: 19030167
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease".
    Yilmaz Y; Dolar E; Ulukaya E
    J Pediatr Gastroenterol Nutr; 2009 Sep; 49(3):371; author reply 371-2. PubMed ID: 19707105
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice.
    Tiniakos DG; Papatheodoridis GV
    Hepatology; 2010 Feb; 51(2):717-8. PubMed ID: 19918977
    [No Abstract]   [Full Text] [Related]  

  • 17. Keratin-18 as a marker of steatohepatitis.
    Gonzalez-Quintela A; Lojo S; Otero E; Perez LF
    Hepatology; 2007 Feb; 45(2):545. PubMed ID: 17256723
    [No Abstract]   [Full Text] [Related]  

  • 18. What is the best indicator for evaluating treatment response in nonalcoholic fatty liver disease: histology or aminotransferase levels?
    Akyuz F; Demir K; Cevikbas U; Okten A
    J Gastroenterol Hepatol; 2005 Jan; 20(1):167-8. PubMed ID: 15610470
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD.
    Liu Z; Ren Q; Mu H; Zeng Y; An Z; He H
    BMC Gastroenterol; 2024 May; 24(1):182. PubMed ID: 38778244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?
    Yu AS; Keeffe EB
    Am J Gastroenterol; 2003 May; 98(5):955-6. PubMed ID: 12809814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.